Merck
Executive Summary
Earnings per share growth for the full year is projected to be 13%-15%. "The Pink Sheet" (May 1, p. 23) incorrectly referred to a projected revenue growth rate. In addition, the projection that Zocor sales will top $3 bil. in the U.S. is an extrapolation by "The Pink Sheet" based on the first quarter performance of the drug